bioMérieux Earns Record-High Number of Clinical Laboratory Awards for Excellence

DURHAM, N.C. – Sept. 27, 2021 — bioMérieux, a world leader in in vitro diagnostics, infectious disease management, and service and system performance, was recently awarded eight IMV ServiceTrak™ Clinical Laboratory Awards in the areas of Immunoassay, AST/ID and Blood Culture excellence. These awards signify bioMérieux’s distinction in comprehensive service performance.

IMV, part of Science and Medicine Group, is the leading market research and business intelligence provider to the laboratory diagnostic industry. IMV ServiceTrak Clinical Awards are presented each year to the manufacturers with the highest satisfied responses in 10 categories, representing the best in customer satisfaction, performance, and service.

bioMérieux was honored to win five ServiceTrak Clinical Awards in 2019 and six awards in 2020. In 2021, laboratory professionals have rated bioMérieux’s technology platforms, system performance and service to be the best in the following categories:

• Immunoassay:
  • Best Service
  • Best System Performance
• AST/ID:
  • Best Service (tied)
  • Best Customer Satisfaction
  • Best System Performance (tied)
• Blood Culture:
  • Best Service
  • Best Customer Satisfaction
  • Best System Performance

In addition, BioFire Diagnostics, bioMérieux’s Global Center of Excellence for Molecular Diagnostics, won the ServiceTrak awards for Best Customer Satisfaction and Best System Performance in the Molecular Diagnostics category.

These awards exemplify bioMérieux’s commitment to public health, providing increasingly sophisticated diagnostic testing solutions and fast, accurate, and actionable information to assist physicians in the diagnosis, treatment and care of patients.

"On behalf of IMV, I would like to congratulate bioMérieux on winning eight ServiceTrak™ Clinical Awards,” said Tom Ogburn, Chief Commercial Officer for Science and Medicine Group, parent company of IMV. "Their focus on important attributes such as quality, reliability and service exemplify an unparalleled commitment to their customers. The achievement of winning more awards than any other company should be celebrated by the organization, truly a phenomenal effort."

Along with its high-quality diagnostic systems, bioMérieux continues to prioritize the commitment and performance of its Customer Support Operations. The organization extends more than 20 years of business communications training to its team members, ensuring exceptional service as part of bioMérieux’s culture.

“This is a monumental recognition for bioMérieux as we are very passionate about providing an outstanding experience to our customers,” said Dan Biondo, Vice President, Customer Support Operations, bioMérieux, Inc. “Throughout the pandemic and its challenges, our service teams continue to go above and beyond to ensure every customer’s need is met. We are very proud to have won these awards to recognize all of their efforts to maintain the highest quality of customer service daily.”

bioMérieux’s commitment to deliver innovative diagnostic systems, service, and customer satisfaction further supports the successful activation of antimicrobial stewardship efforts, as well as bioMérieux’s essential role in the betterment of public health.

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of international sales (outside of France).

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

picture1.png

bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP